Biopharma Co. Aridis Launches $28M IPO For Clinical Trials
Biopharmaceutical company Aridis Pharmaceuticals Inc. launched an estimated $28 million initial public offering on Monday to help fund clinical trials involving immunotherapies for infectious diseases that are resistant to traditional drugs....To view the full article, register now.
Already a subscriber? Click here to view full article